Trial Profile
Study to Assess the Safety and Tolerability of Ascending Single Doses of REGN2009 in Healthy Volunteers
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 12 Nov 2014
Price :
$35
*
At a glance
- Drugs REGN 2009 (Primary)
- Indications Unspecified
- Focus Adverse reactions; First in man
- Sponsors Regeneron Pharmaceuticals
- 09 Nov 2014 Status changed from recruiting to completed as reported by ClinicalTrials.gov record.
- 28 Mar 2014 New trial record